Evaluation of SARS-CoV2-specific serum parameters in blood samples of hospitalized COVID-19 patients with acute disease and recovered COVID-19 patients with asymptomatic disease (HTXCOV-01K)

Evaluation of SARS-CoV2-specific serum parameters in blood samples of hospitalized COVID-19 patients with acute disease and recovered COVID-19 patients with asymptomatic disease (HTXCOV-01K) - COVIAS_K

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00028158

Enrollment

Registered

2022-02-21

Start date

2021-11-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: single blood drawing

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Existence of consent to participate in the study. 2. The patient is at least 18 years old and capable of giving consent. In the case of patients of legal age who are unable to give their consent, consent can be given by a legal guardian. 3. Detection of at least one-time positive SARS-CoV-2 swab PCR test or antibody test for COVID-19. 4. Acute hospitalized due to COVID-19 pneumonia OR recovered with an asymptomatic course. 5. After prior consultation with the sponsor, patients who have received at least one vaccination against the SARS-CoV-2 virus may also be included.

Exclusion criteria

Exclusion criteria: 1. Any illness or condition that does not medically permit the blood sample in the opinion of the consenting physician.

Design outcomes

Primary

Measure	Time frame
This trial does not fall under the German drug or device law as no drug is applied; only one blood drawing takes place. The aim of this trial is to compare SARS-CoV-2-specific serum parameters (e.g. IgG-, IgA-, IgM-level, lipids etc.) of different populations (patients with acute COVID-19 disease as well as recovered SARS-CoV-2-patients with asymptomatic disease). This trial is designed to establish assays that can be used in the future to plan clinical trials with patients suffering from COVID-19. The results of this trial might also be used in drug development projects.	—

Measure

Time frame

This trial does not fall under the German drug or device law as no drug is applied; only one blood drawing takes place. The aim of this trial is to compare SARS-CoV-2-specific serum parameters (e.g. IgG-, IgA-, IgM-level, lipids etc.) of different populations (patients with acute COVID-19 disease as well as recovered SARS-CoV-2-patients with asymptomatic disease). This trial is designed to establish assays that can be used in the future to plan clinical trials with patients suffering from COVID-19. The results of this trial might also be used in drug development projects.

—

Countries

Germany

Contacts

Public ContactSelina Hein

Katholisches Klinikum Koblenz-Montabaur

s.hein@kk-km.de+492614964075

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026